Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma

International Journal of Urology : Official Journal of the Japanese Urological Association
Manuela Schmidinger, Jutta Bergler-Klein

Abstract

Targeted agents have significantly improved outcomes in patients with metastatic renal cell carcinoma, and are changing long-term expectations in these patients. Experience with these agents highlights a distinct safety and tolerability profile, differing from that observed with conventional chemotherapy and radiotherapy. Cardiovascular adverse events have been observed when treating with targeted agents. This is of particular importance for patients with metastatic renal cell carcinoma who are elderly and present with significant comorbidities. A multidisciplinary approach and close collaboration between oncologists and cardiologists is essential for optimal management of cardiovascular adverse events. Strategies for the management of these adverse events include assessment of cardiovascular status at baseline and at regular intervals, patient education, and the use of supportive medication. Effective therapy management allows patients with cardiovascular adverse events to receive and continue targeted therapy with careful monitoring. Implementation of therapy management measures contributes towards maximizing treatment outcomes with targeted agents in patients with metastatic renal cell carcinoma.

References

Jun 1, 1996·Journal of Cardiovascular Pharmacology·R YangH Jin
Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Sep 4, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·J BriegerH J Decker
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I Rini, Eric J Small
Apr 7, 2005·World Journal of Urology·John S LamRobert A Figlin
Jul 25, 2006·Nature Medicine·Risto KerkeläThomas Force
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jan 31, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Xiaolei ZhuChirag R Parikh
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Willem J van HeeckerenScot C Remick
Sep 1, 2007·Journal of Hypertension·Giuseppe ManciaUNKNOWN ESH-ESC Task Force on the Management of Arterial Hypertension
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manuela SchmidingerHerwig Schmidinger
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dana D Hu-LoweSteve L Bender
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H IzzedineJ P Spano
May 15, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Pankaj Bhargava
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Sep 8, 2009·Acta Oncologica·George S OrphanosAlexandros G Ardavanis
Nov 7, 2009·Clinical Genitourinary Cancer·Ana M Molina, Robert J Motzer
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Feb 2, 2010·Journal of the American College of Cardiology·Daniela CardinaleCarlo M Cipolla
Mar 11, 2010·Expert Review of Anticancer Therapy·Bernard Escudier
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriJoaquim Bellmunt
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierVesna Sneller
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
May 28, 2010·Cancer Investigation·Manuela SchmidingerAlain Ravaud
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Working Group
Nov 10, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James E Ward, Walter M Stadler
Feb 1, 2011·European Urology·Giuseppe Di LorenzoCarlo Buonerba
Apr 30, 2011·Journal of the National Cancer Institute·Brian I RiniRobert J Motzer
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian I RiniOlivier Rixe
Jun 18, 2011·Drugs in R&D·Bernard Escudier, Martin Gore

❮ Previous
Next ❯

Citations

Jun 2, 2012·International Journal of Urology : Official Journal of the Japanese Urological Association·Alain Ravaud
Feb 22, 2018·European Journal of Heart Failure·Pietro AmeriUNKNOWN Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology
Jul 30, 2014·Expert Review of Anticancer Therapy·Anna M CzarneckaBrian Rini
Jan 5, 2021·European Heart Journal Cardiovascular Imaging·Maria Klara Frey, Jutta Bergler-Klein
Sep 1, 2013·EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [et Al.]·Manuela Schmidinger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.